However, and very importantly, when agonists for both CXCR4 and CB2 receptors are administered simultaneously, heteromers are formed, and CXCR4-mediated cell migration of breast cancer cells is reduced relative to CXCR4 activation alone [27]. The gene discussed is CXCR4; the disease is breast cancer.